The incidence and prognostic impact of late bleeding complications after transcatheter aortic valve
P eriprocedural bleeding events after transcatheter aortic valve replacement (TAVR) are frequent and have been shown to be associated with worse prognosis (1) (2) (3) (4) (5) (6) . Although early bleeding complications after TAVR are related mainly to procedural or technical factors (e.g., vascular complications) (7) (8) (9) , the cause, nature, and impact of late bleeding (after 30 days) in this population remain unknown.
Given the advanced age and the presence of multiple comorbidities, including atrial fibrillation (AF) or coronary artery disease, among the currently treated TAVR population (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , it is to be expected that late bleeding events, especially in the context of routine dual-antiplatelet therapy and/or anticoagulation, will be frequent and will adversely affect long-term prognosis (21) . As a first step to better define and individualize antithrombotic therapy after TAVR (3, 21, 22) and to inform future trials for this population, we sought to characterize the incidence, predictors, and impact of major late Research Consortium criteria as described in the PARTNER trial protocol (14, 15 ). An independent clinical events committee adjudicated all adverse events.
Further extensive review of the source documents was performed by one of the authors (P.G.) to better characterize the causes of bleeding events. Independent core laboratories analyzed all echocardiograms and electrocardiograms. An independent academic biostatistics group performed all data analyses.
STATISTICAL ANALYSIS. Continuous variables are summarized as mean AE SD or as medians and quartiles, as appropriate, and were compared using Student t tests or Mann-Whitney rank sum tests accordingly.
Categorical variables were compared using chi-square or Fisher exact tests. Survival curves for time-to-event variables were constructed on the basis of all available follow-up data using Kaplan-Meier estimates, and comparisons were performed using the log-rank test. Tables 2 and 3 . Patients with MLBCs were more frequently male and hypertensive, had more baseline AF, and had lower baseline hemoglobin and white blood cell counts. Values are n (%). In cases of multiple bleeding events between 30 and 365 days, only the first bleeding event was counted. There were 11 patients of 142 with more than 1 late major bleeding event. *Includes 8 patients with initial falls and subsequent neurological bleeding. †Hip surgery and knee surgery. ‡At a subsequent percutaneous coronary intervention complicated by vessel perforation.
TAVR ¼ transcatheter aortic valve replacement.
Généreux et al. No major differences were seen in antiplatelet therapy (aspirin and/or clopidogrel) regimens between the 2 groups at 30-day and 6-month follow-up (Online Appendix).
PREDICTORS OF MLBCS.
Variables associated with MLBCs are summarized in Table 4 . 
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Comparison of cumulative adverse event rates through 1 year in patients with late bleeding compared with patients with no late bleeding. (A) All-cause mortality, (B) cardiac mortality, (C) rehospitalization, and (D) major stroke. CI ¼ confidence interval; HR ¼ hazard ratio.
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appear to be related mainly to patients' bleeding susceptibility, which is often "triggered" by the antithrombotic agent used. Unsurprisingly, GI bleeding was the most frequently identifiable source of major bleeding after 30 days. Bleeding from arteriovenous malformation distributed throughout the GI tract is a well-described syndrome (Heyde's syndrome) associated with severe aortic stenosis, accounting for a significant proportion of GI bleeding in this population (28, 29) . Similarly, benign and 
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The detrimental impact of major late bleeding is constant among all major subgroups. STS ¼ Society of Thoracic Surgeons; other abbreviations as in Figure 1 .
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